Non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease in the world, affecting 25% of the population. Around 6% of people with NAFLD will be at risk of developing advanced fibrosis, but symptoms often first occur very late from a decompensated cirrhosis. We need better referral pathways to identify and treat patients with advanced fibrosis. Non-invasive tests such as FIB-4 and NFS can be used in primary care to identify patients who will benefit from a referral to secondary care.
|Bidragets oversatte titel||Nonalkoholisk fedtlever-sygdom ved overvægt og metabolisk syndrom|
|Tidsskrift||Ugeskrift for Laeger|
|Status||Udgivet - 17 okt. 2022|
- Non-alcoholic Fatty Liver Disease/diagnosis
- Liver Cirrhosis/complications
- Referral and Consultation